Payment overview · 2025
General Payments
$20.54
1 reported records · 1 companies
Healthcare provider profile · identity verified
Bryan J. Kellenberger, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · SHERMAN, IL · NPI 1275733073
Verified facts
What the public records show
CMS Open Payments records show Bryan J. Kellenberger, M.D. received $20.54 in general payments during 2025 across 1 reported records.
Novo Nordisk Inc accounted for 100.0% of that reported general-payment amount.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $20.54 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $20.54 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
Payment records were found, but the reported records did not identify a specific associated product for this analysis.
Public prescribing for products named in payments
There is no explicit payment-product set available for a Part D comparison.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
74 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 811 | 198 |
| Levothyroxine Sodium | Levothyroxine Sodium | 486 | 121 |
| Lisinopril | Lisinopril | 478 | 120 |
| Metoprolol Succinate | Metoprolol Succinate | 424 | 105 |
| Losartan Potassium | Losartan Potassium | 393 | 100 |
| Amlodipine Besylate | Amlodipine Besylate | 377 | 95 |
| Omeprazole | Omeprazole | 336 | 86 |
| Hydrochlorothiazide | Hydrochlorothiazide | 331 | 80 |
| Furosemide | Furosemide | 296 | 76 |
| Pantoprazole Sodium | Pantoprazole Sodium | 283 | 72 |
| Tramadol Hcl | Tramadol Hcl | 269 | 64 |
| Potassium Chloride | Potassium Chloride | 266 | 59 |
| Fluoxetine Hcl | Fluoxetine Hcl | 253 | 55 |
| Simvastatin | Simvastatin | 217 | 57 |
| Metformin Hcl Er | Metformin Hcl | 208 | 55 |
| Pravastatin Sodium | Pravastatin Sodium | 208 | 52 |
| Sertraline Hcl | Sertraline Hcl | 207 | 48 |
| Eliquis | Apixaban | 198 | 41 |
| Gabapentin | Gabapentin | 186 | 51 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 180 | 51 |
| Tamsulosin Hcl | Tamsulosin Hcl | 178 | 51 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 177 | 24 |
| Metformin Hcl | Metformin Hcl | 176 | 48 |
| Lorazepam | Lorazepam | 164 | 31 |
| Allopurinol | Allopurinol | 162 | 46 |
| Metoprolol Tartrate | Metoprolol Tartrate | 160 | 43 |
| Trazodone Hcl | Trazodone Hcl | 144 | 32 |
| Warfarin Sodium | Warfarin Sodium | 141 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 140 | 31 |
| Citalopram Hbr | Citalopram Hydrobromide | 129 | 23 |
| Famotidine | Famotidine | 129 | 26 |
| Carvedilol | Carvedilol | 121 | 29 |
| Alprazolam | Alprazolam | 119 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 102 | 40 |
| Glipizide | Glipizide | 100 | 24 |
| Lovastatin | Lovastatin | 89 | 22 |
| Atenolol | Atenolol | 88 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 85 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 81 | 23 |
| Rybelsus | Semaglutide | 74 | 12 |
| Bupropion Xl | Bupropion Hcl | 73 | 16 |
| Enalapril Maleate | Enalapril Maleate | 72 | 20 |
| Spironolactone | Spironolactone | 72 | 17 |
| Ezetimibe | Ezetimibe | 70 | 17 |
| Glipizide Er | Glipizide | 70 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 65 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 63 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 62 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 61 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 61 | 17 |
| Prednisone | Prednisone | 57 | 36 |
| Montelukast Sodium | Montelukast Sodium | 54 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 52 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 52 | suppressed |
| Ondansetron Odt | Ondansetron | 47 | 15 |
| Donepezil Hcl | Donepezil Hcl | 46 | 11 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 45 | suppressed |
| Celecoxib | Celecoxib | 45 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 44 | 12 |
| Meloxicam | Meloxicam | 44 | 11 |
| Jardiance | Empagliflozin | 43 | 11 |
| Mirtazapine | Mirtazapine | 43 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 40 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 40 | suppressed |
| Finasteride | Finasteride | 39 | suppressed |
| Xarelto | Rivaroxaban | 39 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 38 | suppressed |
| Ibuprofen | Ibuprofen | 36 | suppressed |
| Ramipril | Ramipril | 36 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 36 | 23 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 35 | suppressed |
| Irbesartan | Irbesartan | 34 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 33 | 30 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 33 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 33 | suppressed |
| Topiramate | Topiramate | 33 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 32 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 32 | 24 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 31 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 31 | suppressed |
| Chlorthalidone | Chlorthalidone | 30 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 29 | suppressed |
| Mounjaro | Tirzepatide | 29 | suppressed |
| Pregabalin | Pregabalin | 29 | suppressed |
| Clonazepam | Clonazepam | 28 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 27 | suppressed |
| Cephalexin | Cephalexin | 27 | 20 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 27 | suppressed |
| Verapamil Er | Verapamil Hcl | 27 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 26 | suppressed |
| Ozempic | Semaglutide | 26 | suppressed |
| Nifedipine Er | Nifedipine | 25 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 25 | suppressed |
| Temazepam | Temazepam | 25 | suppressed |
| Diazepam | Diazepam | 24 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Gemfibrozil | Gemfibrozil | 23 | suppressed |
| Januvia | Sitagliptin Phosphate | 23 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 23 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 23 | suppressed |
| Amoxicillin | Amoxicillin | 22 | 17 |
| Buspirone Hcl | Buspirone Hcl | 22 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 22 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | suppressed |
| Estradiol | Estradiol | 20 | suppressed |
| Fenofibrate | Fenofibrate | 20 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 20 | suppressed |
| Calcitriol | Calcitriol | 19 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 18 | suppressed |
| Torsemide | Torsemide | 18 | suppressed |
| Azithromycin | Azithromycin | 17 | 14 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 17 | 17 |
| Indapamide | Indapamide | 17 | suppressed |
| Lamotrigine | Lamotrigine | 17 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Nabumetone | Nabumetone | 17 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 17 |
| Risperidone | Risperidone | 17 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Glimepiride | Glimepiride | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 11 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Entresto | Sacubitril/Valsartan | 14 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Dofetilide | Dofetilide | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 13 | suppressed |
| Latanoprost | Latanoprost | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Trimethoprim | Trimethoprim | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Nystatin | Nystatin | 12 | 11 |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Serevent Diskus | Salmeterol Xinafoate | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $20.54 · 1 records | Novo Nordisk Inc | — | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error